Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2012-12-20

FDA Approved: LEVOTHYROXINE SODIUM — Supplemental Application (Fresenius Kabi USA, LLC)

View source ↗

Summary

FDA approved a supplemental application for Levothyroxine Sodium (Levothyroxine Sodium Anhydrous) by Fresenius Kabi USA, LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LEVOTHYROXINE SODIUM (levothyroxine sodium)

Snippet

SUPPL AP for LEVOTHYROXINE SODIUM (LEVOTHYROXINE SODIUM ANHYDROUS)